Gastrointestinal absorption of Tamiflu in critically ill patients with H1N1

Feb 16, 2010

An increased dosage of Tamiflu (oseltamivir) for patients with critical illness is unlikely to be required in the treatment of pandemic (H1N1) influenza, contrary to current international guidelines, found a new study in CMAJ (Canadian Medical Association Journal) .

World Health Organization (WHO) guidelines recommend that all critically ill patients should be treated with and if the patient was unresponsive to standard doses or critically ill, a higher dose should be considered.

The CMAJ study looked at the gastrointestinal absorption of Tamiflu in 44 patients, 18 years of age or older, with suspected or confirmed pandemic (H1N1) influenza who were admitted to nine ICUs in two cities in Canada (Winnipeg and Ottawa) and Tarragona, Spain because of respiratory failure. As critically ill patients may have gastrointestinal absorption issues, guidelines suggest higher doses of Tamiflu.

"Studying the absorption ability of Tamiflu in the critically ill became a priority with the large number of patients needing ICU and ventilation support," writes lead author Dr. Anand Kumar, Health Sciences Centre, University of Manitoba and coauthors. "Also, the number of suffering from H1N1 related critical illnesses were large which raised the question about whether the dose should be adjusted upwards with increased body weight."

Blood sampling indicated that the 75 mg twice daily dosage of Tamiflu was well absorbed in critically ill patients with respiratory failure. Blood levels of the antiviral were similar or higher than levels in ambulatory patients with a similar dosage. Patients with kidney dysfunction requiring dialysis needed an adjusted dose but adjustment for obesity was not required.

"The findings of this study suggest that an increased Tamiflu dosage is unlikely to be necessary in such cases based on either insufficient drug absorption or altered distribution pharmacokinetics," conclude the authors.

Explore further: New research demonstrates benefits of national and international device registries

More information: www.cmaj.ca

add to favorites email to friend print save as pdf

Related Stories

Drug-resistant swine flu cluster on Vietnam train

Dec 09, 2009

(PhysOrg.com) -- A cluster of seven people infected with a Tamiflu-resistant strain of pandemic H1N1 influenza has been identified in Vietnam by a team including Oxford researchers.

Tamiflu touted for child use

Nov 16, 2007

The maker of the anti-viral Tamiflu said the drug is effective for treatment and prevention of influenza in young children.

WHO says Tamiflu still works against swine flu

Nov 26, 2009

(AP) -- The World Health Organization says isolated cases of drug-resistant swine flu in Britain and the United States have not changed the agency's assessment of the disease.

Disease severity in H1N1 patients

Jan 21, 2010

A new study published in CMAJ (Canadian Medical Association Journal) concerning the severity of H1N1 influenza has found that admissions to an intensive care unit (ICU) were associated with a longer interval between sympto ...

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.